RxDoctor Payments Data

Mark Glotkowski, PA

Physician Assistant · Ann Arbor, MINPI 1821398660

Payments from drug & device makers

$9,489in general payments, 2019–2025

Across 118 payments — averaging $80.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$8K
  • Otsuka America Pharmaceutical, Inc.$537
  • Alkermes, Inc.$315
  • Johnson & Johnson$282
  • Lundbeck LLC$272
  • Indivior Inc.$181
  • plus $394 from 8 others

What the payments were for

  • Consulting fees$6,00063%
  • Travel & lodging$8659%
  • Food & beverage$2,53827%
  • Education$851%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,489 in reported general payments places this provider in the 95th percentile of 5,453 physician assistant providers in Michigan.

See all physician assistant providers in Michigan

Medicare billing

Part B allowed, 2024
$89,864
Medicare patients
154
Services billed
793

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate81$667,339
Invega SustennaPaliperidone Palmitate146$400,663
RexultiBrexpiprazole186$269,923
VraylarCariprazine Hcl107$161,570
AristadaAripiprazole Lauroxil28$61,860
TrintellixVortioxetine Hydrobromide124$59,313
Abilify MaintenaAripiprazole22$58,988
LybalviOlanzapine/Samidorphan Malate28$44,536
GeodonZiprasidone Hcl12$42,719
CaplytaLumateperone Tosylate19$37,215
NuedextaDextromethorphan Hbr/Quinidine28$29,112
VivitrolNaltrexone Microspheres17$27,954
Fluphenazine Hcl119$22,455
AuvelityDextromethorphan Hbr/Bupropion22$22,132
Aripiprazole270$15,831

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$157$667,33981 claims
Johnson & JohnsonInvega Sustenna$282$400,663146 claims
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$537$328,911208 claims
AbbVieVraylar$75$161,570107 claims
Alkermes, Inc.Aristada, Lybalvi, Vivitrol$315$134,35073 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$61$37,21519 claims
Avanir Pharmaceuticals, Inc.Nuedexta$12$29,11228 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,453 physician assistant providers in Michigan.

Other physician assistant in Ann Arbor

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →